Behaviour of breast cancer may vary according to the presence of certain hormone receptors and other markers in cancer cells. Kisqali 600mg tablet is a targeted drug for cancer treatment which is usually prescribed to patients suffering from hormone receptor-positive (HR positive) and HER2 negative advanced or metastatic breast cancer. How Does Kisqali Help Control the Progression of Breast Cancer? The tablet is composed of ribociclib, which is an inhibitor of CDK4/6 enzymes